Francisco C Villafuerte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7531135/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global Research Expedition on Altitude-related Chronic Health 2018 Iron Infusion at High Altitude Reduces Hypoxic Pulmonary Vasoconstriction Equally in Both Lowlanders and Healthy Andean Highlanders. Chest, 2022, 161, 1022-1035.	0.8	8
2	High-Altitude Erythrocytosis: Mechanisms of Adaptive and Maladaptive Responses. Physiology, 2022, 37, 175-186.	3.1	12
3	Acid-base balance at high altitude in lowlanders and indigenous highlanders. Journal of Applied Physiology, 2022, 132, 575-580.	2.5	5
4	Global Reach 2018: Sympathetic neural and hemodynamic responses to submaximal exercise in Andeans with and without chronic mountain sickness. American Journal of Physiology - Heart and Circulatory Physiology, 2022, , .	3.2	1
5	ARID1B, a molecular suppressor of erythropoiesis, is essential for the prevention of Monge's disease. Experimental and Molecular Medicine, 2022, 54, 777-787.	7.7	6
6	Global REACH 2018: Andean highlanders, chronic mountain sickness and the integrative regulation of resting blood pressure. Experimental Physiology, 2021, 106, 104-116.	2.0	12
7	The 2018 Global Research Expedition on Altitude Related Chronic Health (Global REACH) to Cerro de Pasco, Peru: an Experimental Overview. Experimental Physiology, 2021, 106, 86-103.	2.0	24
8	Protective role of estrogen against excessive erythrocytosis in Monge's disease. Experimental and Molecular Medicine, 2021, 53, 125-135.	7.7	27
9	Potential Protective Effect from COVID-19 Conferred by Altitude: A Longitudinal Analysis in Peru During Full Lockdown. High Altitude Medicine and Biology, 2021, 22, 209-224.	0.9	16
10	Global REACH 2018: Influence of excessive erythrocytosis on coagulation and fibrinolytic factors in Andean highlanders. Experimental Physiology, 2021, 106, 1335-1342.	2.0	1
11	Effect of exercise training in rats exposed to chronic hypoxia: Application for Monge's disease. Physiological Reports, 2021, 9, e14750.	1.7	2
12	Global REACH 2018: dysfunctional extracellular microvesicles in Andean highlander males with excessive erythrocytosis. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H1851-H1861.	3.2	10
13	Peruvian research: striving for the highest standards. Lancet, The, 2021, 397, 1805-1806.	13.7	0
14	Global Reach 2018: Nitric oxide-mediated cutaneous vasodilation is reduced in chronic, but not acute, hypoxia independently of enzymatic superoxide formation. Free Radical Biology and Medicine, 2021, 172, 451-458.	2.9	3
15	Global REACH 2018: the adaptive phenotype to life with chronic mountain sickness and polycythaemia. Journal of Physiology, 2021, 599, 4021-4044.	2.9	13
16	Global REACH 2018: volume regulation in high-altitude Andeans with and without chronic mountain sickness. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 321, R504-R512.	1.8	8
17	Subâ€maximal aerobic exercise training reduces haematocrit and ameliorates symptoms in Andean highlanders with chronic mountain sickness. Experimental Physiology, 2021, 106, 2198-2209.	2.0	5
18	Increased hypoxic proliferative response and gene expression in erythroid progenitor cells of Andean highlanders with chronic mountain sickness. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318, R49-R56.	1.8	16

FRANCISCO C VILLAFUERTE

#	Article	IF	CITATIONS
19	Office and Ambulatory Arterial Hypertension in Highlanders. Hypertension, 2020, 76, 1962-1970.	2.7	16
20	Adaptive Potential of the Heme Oxygenase/Carbon Monoxide Pathway During Hypoxia. Frontiers in Physiology, 2020, 11, 886.	2.8	19
21	Global REACH 2018: The carotid artery diameter response to the cold pressor test is governed by arterial blood pressure during normoxic but not hypoxic conditions in healthy lowlanders and Andean highlanders. Experimental Physiology, 2020, 105, 1742-1757.	2.0	2
22	Reevaluation of excessive erythrocytosis in diagnosing chronic mountain sickness in men from the world's highest city. Blood, 2020, 136, 1884-1888.	1.4	23
23	High-Altitude Hypoxia Decreases Plasma Erythropoietin Soluble Receptor Concentration in Lowlanders. High Altitude Medicine and Biology, 2020, 21, 92-98.	0.9	12
24	Global Reach 2018 Heightened α-Adrenergic Signaling Impairs Endothelial Function During Chronic Exposure to Hypobaric Hypoxia. Circulation Research, 2020, 127, e1-e13.	4.5	21
25	Highs and lows of sympathetic neurocardiovascular transduction: influence of altitude acclimatization and adaptation. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H1240-H1252.	3.2	20
26	Relationships Between Chemoreflex Responses, Sleep Quality, and Hematocrit in Andean Men and Women. Frontiers in Physiology, 2020, 11, 437.	2.8	10
27	Global REACH 2018: renal oxygen delivery is maintained during early acclimatization to 4,330 m. American Journal of Physiology - Renal Physiology, 2020, 319, F1081-F1089.	2.7	8
28	Shortâ€ŧerm Subâ€maximal Aerobic Training Reduces Hematocrit and Symptomatology in Andean Highlanders with Monge's Disease. FASEB Journal, 2020, 34, 1-1.	0.5	0
29	Abstract MP26: Endothelial-derived Microvesicles From Andean Highlanders With Excessive Erythrocytosis Induce A Deleterious Cardiomyocyte Phenotype. Hypertension, 2020, 76, .	2.7	Ο
30	Abstract 14993: Dysfunctional Extracellular Microvesicles in Andean Highlanders With Excessive Erythrocytosis. Circulation, 2020, 142, .	1.6	0
31	The Genetic Architecture of Chronic Mountain Sickness in Peru. Frontiers in Genetics, 2019, 10, 690.	2.3	12
32	Global Reach 2018: reduced flow-mediated dilation stimulated by sustained increases in shear stress in high-altitude excessive erythrocytosis. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H991-H1001.	3.2	12
33	Global REACH 2018. Hypertension, 2019, 73, 1327-1335.	2.7	44
34	Genetic variants at the <i>EGLN1</i> locus associated with highâ€altitude adaptation in Tibetans are absent or found at low frequency in highland Andeans. Annals of Human Genetics, 2019, 83, 171-176.	0.8	19
35	The overlooked significance of plasma volume for successful adaptation to high altitude in Sherpa and Andean natives. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16177-16179.	7.1	58
36	Global REACH: Assessment of Brady-Arrhythmias in Andeans and Lowlanders During Apnea at 4330 m. Frontiers in Physiology, 2019, 10, 1603.	2.8	6

#	Article	IF	CITATIONS
37	Excessive erythrocytosis in highâ€altitude residents is associated with modest impairments in shortâ€ŧerm memory and processing speed. FASEB Journal, 2019, 33, 551.2.	0.5	0
38	Increased Serum Erythropoietin despite Normalized Hb Concentration and Arterial O 2 Saturation in Chronic Mountain Sickness after Isovolemic Hemodilution. FASEB Journal, 2019, 33, lb592.	0.5	0
39	Adaptive Servoventilation as Treatment for Central Sleep Apnea Due to High-Altitude Periodic Breathing in Nonacclimatized Healthy Individuals. High Altitude Medicine and Biology, 2018, 19, 178-184.	0.9	25
40	Excessive Erythrocytosis and Cardiovascular Risk in Andean Highlanders. High Altitude Medicine and Biology, 2018, 19, 221-231.	0.9	46
41	Upward Shift and Steepening of the Blood Pressure Response to Exercise in Hypertensive Subjects at High Altitude. Journal of the American Heart Association, 2018, 7, .	3.7	8
42	Increased hypoxic proliferative response in PBMCsâ€derived erythroid progenitor cells of Andean highlanders with Chronic Mountain Sickness. FASEB Journal, 2018, 32, 858.2.	0.5	0
43	Differences in Peak VO2 Among Healthy Andean Highlanders and Males with Chronic Mountain Sickness Before and After Isovolemic Hemodilution at 4350m. FASEB Journal, 2018, 32, lb412.	0.5	Ο
44	Hemeâ€oxygenase 2 (HMOX2) variants associated with evolutionary adaptation and hemoglobin concentration in Tibetans are common in Andean Highlanders. FASEB Journal, 2018, 32, lb413.	0.5	0
45	Increased Levels of Interleukinâ€6 (ILâ€6) in Andean Males with Chronic Mountain Sickness and Seaâ€Level Participants After One Day at High Altitude May Reflect Differences in ILâ€6 Regulation. FASEB Journal, 2018, 32, Ib479.	0.5	1
46	Chronic Mountain Sickness: Clinical Aspects, Etiology, Management, and Treatment. High Altitude Medicine and Biology, 2016, 17, 61-69.	0.9	160
47	Plasma soluble erythropoietin receptor is decreased during sleep in Andean highlanders with Chronic Mountain Sickness. Journal of Applied Physiology, 2016, 121, 53-58.	2.5	13
48	Blood pressure response to six-minute walk test in hypertensive subjects exposed to high altitude: effects of antihypertensive combination treatment. International Journal of Cardiology, 2016, 219, 27-32.	1.7	16
49	SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. Experimental Hematology, 2016, 44, 483-490.e2.	0.4	13
50	Left ventricular adaptation to high altitude: speckle tracking echocardiography in lowlanders, healthy highlanders and highlanders with chronic mountain sickness. International Journal of Cardiovascular Imaging, 2015, 31, 743-752.	1.5	25
51	Blood Pressure Response to Exercise in Hypertensive Subjects Exposed to High Altitude and Treatment Effects. Journal of the American College of Cardiology, 2015, 66, 2806-2807.	2.8	12
52	New genetic and physiological factors for excessive erythrocytosis and Chronic Mountain Sickness. Journal of Applied Physiology, 2015, 119, 1481-1486.	2.5	22
53	Ambulatory Blood Pressure in Untreated and Treated Hypertensive Patients at High Altitude. Hypertension, 2015, 65, 1266-1272.	2.7	60
54	Facilitation by intracellular carbonic anhydrase of Na ⁺ –HCO ₃ ^{â^'} coâ€ŧransport but not Na ⁺ /H ⁺ exchange activity in the mammalian ventricular myocyte. Journal of Physiology, 2014, 592, 991-1007.	2.9	29

FRANCISCO C VILLAFUERTE

#	Article	IF	CITATIONS
55	Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain Sickness. Journal of Applied Physiology, 2014, 117, 1356-1362.	2.5	36
56	Ischemic changes in exercise ECG in a hypertensive subject acutely exposed to high altitude. Possible role of a high-altitude induced imbalance in myocardial oxygen supply–demand. International Journal of Cardiology, 2014, 171, e100-e102.	1.7	25
57	Chronic Mountain Sickness. , 2014, , 429-447.		9
58	Whole-Genome Sequencing Uncovers the Genetic Basis of Chronic Mountain Sickness in Andean Highlanders. American Journal of Human Genetics, 2013, 93, 452-462.	6.2	115
59	Rebuttal to Pro Statements. High Altitude Medicine and Biology, 2013, 14, 218-218.	0.9	1
60	Con: All Dwellers at High Altitude Are Persons of Impaired Physical and Mental Powers: The View from the Andes. High Altitude Medicine and Biology, 2013, 14, 212-213.	0.9	3
61	Exercise Pathophysiology in Patients With Chronic Mountain Sickness. Chest, 2012, 142, 877-884.	0.8	75
62	High-Altitude Pulmonary Hypertension. , 2011, , 1211-1221.		1
63	Chronic Mountain Sickness and the Heart. Progress in Cardiovascular Diseases, 2010, 52, 540-549.	3.1	86
64	Comparison of pH-dependence of Carbonic Anhydrase Activity in vitro and in Living Cells. Biophysical Journal, 2009, 96, 625a.	0.5	4
65	Confocal Imaging Of Extracellular pH With Fluorescein Derivatives. Biophysical Journal, 2009, 96, 298a.	0.5	0
66	S0859, an <i>N</i> yanosulphonamide inhibitor of sodiumâ€bicarbonate cotransport in the heart. British Journal of Pharmacology, 2008, 153, 972-982.	5.4	98
67	Ventilatory response to acute hypoxia in transgenic mice over-expressing erythropoietin: Effect of acclimation to 3-week hypobaric hypoxia. Respiratory Physiology and Neurobiology, 2007, 158, 243-250.	1.6	13
68	pH-Regulated Na+ Influx into the Mammalian Ventricular Myocyte: The Relative Role of Na+-H+ Exchange and Na+-HCO3- Co-Transport. Journal of Cardiovascular Electrophysiology, 2006, 17, S134-S140.	1.7	44
69	Optimal hemoglobin concentration and high altitude: a theoretical approach for Andean men at rest. Journal of Applied Physiology, 2004, 96, 1581-1588.	2.5	65